Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



02 AUG 14 F

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

Akin, Gump, Strauss, Hauer &	z Feld, L.L.P.		
2. Address	han previously reported		
1333 New Hampshire Avenue	, NW		
3. Principal Place of Business (if differen	at from line 2)		
City: Washington	State/Zip (or C	Country) DC 20036	
4. Contact Name	Telephone	E-mail (optional)	5. Senate II
Bill Paxon	202-887-4000		682-8
7. Client Name			6. House ID
Pharmaceutical Research and	Manufacturers of America		3178
9. Check if this filing amends a p	reviously filed version of this re	port 🗌	
10. Check if this is a Termination INCOME OR EXPEN	Report $\square \Rightarrow$ Termination \mathbf{SES} – Complete Either I	on Date	
INCOME OR EXPEN	Report □ ⇒ Termination SES – Complete Either Ing Firms	on Date	13. Organizations
10. Check if this is a Termination INCOME OR EXPEN 12. Lobbyi INCOME relating to lobbying a	Report □ ⇒ Termination SES – Complete Either Ing Firms	on Date	13
10. Check if this is a Termination INCOME OR EXPEN	Report □ ⇒ Termination SES – Complete Either Ing Firms	ine 12 OR Line 1	13. Organizations
10. Check if this is a Termination INCOME OR EXPEN 12. Lobbyi INCOME relating to lobbying a period was: Less than \$10,000	Report □ ⇒ Termination SES – Complete Either Ing Firms	ine 12 OR Line 1 EXPENSES relativere:	13. Organizations
10. Check if this is a Termination INCOME OR EXPEN 12. Lobbyi INCOME relating to lobbying a period was: Less than \$10,000 \$10,000 or more Provide a good faith estimate, roo	Report	EXPENSES relativere: Less than \$10,000 \$10,000 or more	13. Organizations Ing to lobbying activities for this r
10. Check if this is a Termination INCOME OR EXPEN 12. Lobbyi INCOME relating to lobbying a period was: Less than \$10,000 □ \$10,000 or more ⊠ ⇒ Provide a good faith estimate, rou of all lobbying related income from payments to the registrant by any	Report	EXPENSES relativere: Less than \$10,000 \$10,000 or more 14. REPORTING accounting method.	13. Organizations Ing to lobbying activities for this r \[\begin{array}{cccccccccccccccccccccccccccccccccccc
10. Check if this is a Termination INCOME OR EXPEN 12. Lobbyi INCOME relating to lobbying a period was: Less than \$10,000 □ \$10,000 or more ⊠ ⇒	Report	EXPENSES relativere: Less than \$10,000 \$10,000 or more 14. REPORTING accounting method. Method A. R. Method B. R.	13. Organizations Ing to lobbying activities for this r Barbers Spenses (near Expenses (near Expenses to indice). See instructions for description

LD-2 (REV. 6/98)

Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.I	P. Client Name	Pharmaceuri	h and Manufactur
LOBBYING ACTIVITY. Select as many codes as ne engaged in lobbying on behalf of the client during the reinformation as requested. Attach additional page(s) as	cessary to reflec eporting period.	t the general i	ssue areas in which the
15. General issue area code MMM (one per page)			
16. Specific lobbying issues Medicare Modernization and Prescription Drug A	ct (H.R. 4954)		
17. House(s) of Congress and Federal Agencies contact U.S. House of Representatives Office of the White House	ted 🔲	Check if Nor	ne
18. Name of each individual who acted as a lobbyist in	this issue area	Covered Offic	ial Position (if applicable)
Bill Paxon			
Paul G. Scolese			
19. Interest of each foreign entity in the specific issues listed	on line 16 above	⊠ Ch	eck if None
Signature			Date August 14, 2002

Form LD-2 (Rev. 6/98)

Page

00020321467 1 Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P. Client Name Pharmaceutical Research and Manufacture LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each coc information as requested. Attach additional page(s) as needed. 15. General issue area code PHA (one per page) 16. Specific lobbying issues Title V Prescription Drug User Fee Amendments (H.R. 3448) ☐ Check if None 17. House(s) of Congress and Federal Agencies contacted U.S. House of Representatives 18. Name of each individual who acted as a lobbyist in this issue area Covered Official Position (if applicable) Name Bill Paxon Paul G. Scolese

Signature)

Date August 14, 2002

Printed Name and Title Bill Paxon, Senior Advisor

Form LD-2 (Rev. 6/98)

Page

t